Prelude Therapeutics (PRLD) Change in Accured Expenses (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Change in Accured Expenses data on file, last reported at -$6.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 66.38% year-over-year to -$6.6 million; the trailing twelve-month figure through Mar 2026 stood at -$5.6 million (down 712.88% YoY), and the FY2025 full-year result was -$3.0 million, down 268.81% from the prior year.
• Change in Accured Expenses eased to -$6.6 million in Q1 2026, from -$515000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.4 million in Q4 2023 to a low of -$6.6 million in Q1 2026.
• A 5-year average of -$60882.4 and a median of $896000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses jumped 583.8% in 2022 and sank 389.06% in 2023, its largest moves.
• Tracing PRLD's Change in Accured Expenses over 5 years: stood at $3.2 million in 2022, then jumped by 38.56% to $4.4 million in 2023, then plunged by 64.35% to $1.6 million in 2024, then tumbled by 132.87% to -$515000.0 in 2025, then sank by 1181.94% to -$6.6 million in 2026.
• Business Quant data shows PRLD's Change in Accured Expenses at -$6.6 million in Q1 2026, -$515000.0 in Q4 2025, and -$367000.0 in Q3 2025.